Lipid mediators: Platelet activating factor (PAF): Apart from trypsin, PAF has been extensively targeted in pancreatitis. PAF is a phospholipid
(acetyl-glyceryl-ether-phosphorylcholine) produced by myeloid cells, platelets and
endothelial cells. Intra-arterial delivery of PAFs into the pancreas causes AP
142
. PAF
production in inflammation is mediated by phospholipase A2, and it is degraded by PAF
acetylhydrolase
143
. Its receptor is a G-protein receptor
144
. PAF has a broad range of effects
including increasing vascular permeability, worsening inflammation and initiating cell
death
145
. Its levels are increased in severe biliary pancreatitis
146
in which it was thought to
mediate shock and acute lung injury
147
, and the protective effect of antagonizing it was
shown in multiple models including biliary, choline deficient ethionine supplemented diet
(CDE diet)
148
, caerulein model in rats, and severe biliary pancreatitis in opossums
51
. While
initial clinical trials using lexipafant, a PAF antagonist were promising
149
, the large
definitive clinical trial did not show benefit in OF or mortality, even though local
complications and sepsis were reduced
150
. Whether this was due to a limitation of targeting
PAF or the high prevalence of early OF remains to be studied (please see below).
Unsaturated fatty acids (UFAs): The pancreas by its location is proximal to visceral fat in humans. Several studies report an
increased risk of severe pancreatitis to be associated with an increase in visceral fat
151-154
which ranges from 1-10% of body weight
155
. This fat is composed of adipocytes, the mass
of which is predominantly (>80%) triglyceride
156-158
. This triglyceride is predominantly
composed of UFAs
159, 160
, covalently linked to a glycerol backbone, which when released
by unregulated lipolysis affect severity of AP. Interestingly, adipocyte triglyceride has
become enriched in UFAs like linoleic acid over the last few decades
161
, which mirrors the
15-25% linoleic acid composition of necrosectomy samples from severe AP patients
47, 53
.
Previous studies have shown pancreatic lipases to be present in the adipocytes, damaged
during AP
162
. This results in a morphology known as fat necrosis, which can worsen
pancreatic parenchymal necrosis
49, 53
, but can also occur independently
163, 164
. This
lipolytic fatty acid generation can increase systemic injury during pancreatitis, in parallel
with an increase in serum UFAs such as linoleic and arachidonic acid
165, 166
, which like
visceral fat
15947, 48, 53, 160
are unsaturated. These UFAs when liberated in excess, inhibit
mitochondrial complexes I and V
53
, and increase apoptotic cells in the lungs
17, 48, 49, 53
(similar to patients with acute respiratory distress syndrome
54, 167, 168
), elevate serum
BUN
47, 49, 53, 169
due to renal tubular injury , and result in mortality. Interestingly, elevated
serum levels of TNF-
α, IL-1β, MCP-1 and IL-18 can all be induced during this fatty acid
toxicity, perhaps due to the widespread release of DAMPs. Importantly, inhibition of this
excessive lipolysis can result in prevention of systemic injury, hypercytokinemia and
mortality
47-49, 53
. While it remains to be seen if lipase inhibition will reduce systemic injury
during human AP, it is encouraging to note that the cyclooxygenase inhibitor indomethacin,
which is known to affect the metabolism of UFA products, may reduce progression of
moderate-severe AP.
170
.
Garg and Singh
Page 10
Gastroenterology. Author manuscript; available in PMC 2020 May 01.
A
uthor Man
uscr
ipt
A
uthor Man
uscr
ipt
A
uthor Man
uscr
ipt
A
uthor Man
uscr
ipt